Home › NDC Lookup › Ingredients › Tizanidine Hydrochloride › 59651-0315-77
Tizanidine Hydrochloride 4 mg Capsule, 150-count — NDC 59651-0315-77 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Tizanidine Hydrochloride 4 mg Capsule, 150-count — NDC 59651-315-77 (Billing 59651-0315-77)

by Aurobindo Pharma Limited · 150 CAPSULE in 1 BOTTLE

This is a package of 150 capsules of Tizanidine Hydrochloride 4 mg Capsule from Aurobindo Pharma Limited, marketed since Mar 2020 and currently FDA-listed; retail pharmacies pay about $0.0967 per capsule (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 59651-0315-77
🏷️ FDA NDC (as labeled) 59651-315-77 billing pads the product segment with a zero
This package
Contains150-count Cost per ea$0.0967 NADAC Per package$14.51 / 150 capsules Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.2750/unit · Part D plans $0.3010/unit — full pricing hub ↓
Main listing for product 59651-315 · Also comes in: 1500 capsules 59651-315-15
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 59651-315-77
Product NDC 59651-315
11-digit billing NDC 59651031577
NCPDP billing unit EA — each (per item)
SPL Set ID abab3705-296f-42bd-958f-69205ebda164
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-03-24
Dosage form CAPSULE
Substance TIZANIDINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 75100090100120
GPI class tiZANidine HCl
GCN Seq No 058905
GCN 24434
HICL code 011582
Ingredient (HICL) Tizanidine Hcl
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6H
Therapeutic class — specific (HIC3) Skeletal Muscle Relaxants
AHFS code 12:20.04.00
AHFS class Centrally Acting Skeletal Muscle Relaxnt
FDB label name TIZANIDINE HCL 4 MG CAPSULE
FDB brand name Tizanidine Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 058905
  • GCN: 24434
  • GPI-14 (Medi-Span): 75100090100120
  • HICL (First Databank): 011582
  • AHFS class code: 12:20.04.00
Why two NDCs? The FDA registers this code as 59651-315-77 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 59651-0315-77. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name TIZANIDINE HCL 4 MG CAPSULE Ingredient Tizanidine Hcl
📖 What it is MedlinePlus · NLM

Tizanidine is used to relieve muscle spasms, cramping, and tightness caused by certain conditions including multiple sclerosis (MS, a disease in which the nerves do not function properly and patients may experience weakness, numbness, loss of muscle coordination and problems with vision, speech, and bladder control) and spinal injury. Tizanidine is in a class of medications called skeletal muscle relaxants. It works by slowing action in the brain and nervous system to allow the muscles to relax.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It helps manage spasticity, meaning stiff, tight muscles that are hard to control. It wears off quickly, so it is meant for the times and activities when you most need relief.
  • Food changes how much tizanidine you absorb, and tablets and capsules react differently. The key is to be consistent, either always with food or always without. Tell me or your pre...
  • Dry mouth, sleepiness, tiredness or weakness, and dizziness are the most common. Many people find them mild to moderate. Call your doctor if you faint, see things that are not ther...
  • It is best to avoid it. Alcohol raises the amount of tizanidine in your blood and adds to drowsiness and side effects. The same goes for other sedating medicines, so check with me...
📖 Read our full Tizanidine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.097 $14.51 / 150 capsules
Medicaid paysCMS SDUD · 12 mo $0.2750 $41.25 / 150 capsules
Medicare drug plans payPart D · Q2 2026 $0.3010 $45.15 / 150 capsules
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.206 $0.085
▼ Down 23% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
59651-0315-77 You're viewing this Main listing 150 CAPSULE in 1 BOTTLE $0.0967 / ea $14.51 2020-03-24 — Active
59651-0315-15 59651-315-15 1500 CAPSULE in 1 BAG — — — — Active

You're viewing the smallest of 2 pack sizes for this product.

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 150-count package — 150 capsule in 1 bottle.
How does this package differ from NDC 59651-0315-15?
Both are Tizanidine Hydrochloride 4 mg Capsule — the drug itself is identical. This page's package is the 150-count one, while NDC 59651-0315-15 is the 1500 capsules package.
What NDC number is used to bill for this package of Tizanidine Hydrochloride 4 mg Capsule?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
tizanidine hydrochloride 4 mg 00591-2789-86 Actavis 150 capsules $0.097 AB Availability likely —
Tizanidine Hydrochloride 4 mg 50742-0225-15 Ingenus 150 capsules $0.097 AB Availability likely —
Tizanidine Hydrochloride 4 mgthis 59651-0315-77 Aurobindo 150 capsules $0.097 — Availability likely —
tizanidine hydrochloride 4 mg 72888-0002-15 Advagen 150 capsules $0.097 AB Availability likely —
Tizanidine Hydrochloride 4 mg 75834-0208-15 Nivagen 150 capsules $0.163 AB Discontinued +69%
Tizanidine Hydrochloride 4 mg 42291-0811-15 AvKARE 150 capsules — AB FDA listed —
Tizanidine Hydrochloride 4 mg 46708-0492-08 Alembic 640 capsules — AB FDA listed —
Tizanidine Hydrochloride 4 mg 60505-2649-03 Apotex 30 capsules — AB FDA listed —
Tizanidine Hydrochloride 4 mg 62332-0492-08 Alembic 640 capsules — AB FDA listed —
Tizanidne hydrochloride 4 mg 63629-8872-01 Bryant 150 capsules — AB FDA listed —
Tizanidne hydrochloride 4 mg 67877-0611-05 Ascend 500 capsules — AB FDA listed —
Tizanidine Hydrochloride 4 mg 68788-8747-01 Preferred 100 capsules — AB FDA listed —
tizanidine hydrochloride 4 mg 68788-8776-01 Preferred 100 capsules — AB FDA listed —
Tizanidne hydrochloride 4 mg 68788-8798-01 Preferred 100 capsules — AB FDA listed —
Zanaflex 4 mg 70515-0604-15 Covis 150 capsules — AB FDA listed —
tizanidine hydrochloride 4 mg 70710-1112-04 Zydus 100 capsules — AB FDA listed —
tizanidine hydrochloride 4 mg 70771-1068-04 Zydus 100 capsules — AB FDA listed —
Tizanidine hydrochloride 4 mg 71209-0065-07 Cadila 150 capsules — AB FDA listed —
Tizanidne hydrochloride 4 mg 71335-2209-01 Bryant 150 capsules — AB FDA listed —
tizanidine hydrochloride 4 mg 71335-2559-01 Bryant 1 capsule — AB FDA listed —
Tizanidne hydrochloride 4 mg 72162-1861-02 Bryant 150 capsules — AB FDA listed —
Tizanidine hydrochloride 4 mg 72241-0042-07 Modavar 150 capsules — AB FDA listed —
tizanidine hydrochloride 4 mg 72789-0507-77 PD-Rx 150 capsules — AB FDA listed —
Tizanidine Hydrochloride 4 mg 76420-0901-01 Asclemed 10 capsules — AB FDA listed —
Tizanidine HCL 4 mg 80425-0090-01 Advanced 60 capsules — AB FDA listed —
Tizanidine HCL 4 mg 80425-0144-01 Advanced 30 capsules — AB FDA listed —
tizanidine hydrochloride 4 mg 80425-0474-01 Advanced 30 capsules — AB FDA listed —
Zanaflex 4 mg 83107-0002-15 Legacy 150 capsules — AB FDA listed —
Tizanidine hydrochloride 4 mg 85742-0032-30 Kanchan 150 capsules — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Mar 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 35SW5USQ3G
    A synthetic yellow dye used to color medicines. It helps make tablets, capsules, and liquids visually distinct so patients can easily identify their medication.
  • UNII H3R47K3TBD
    FD&C Blue No. 1 is a synthetic blue dye approved for use in foods and medicines. It serves as a colorant to give the medication its distinctive appearance and help with product identification.
  • UNII H77VEI93A8
    A synthetic yellow dye used to color medications. It helps identify the drug and make it visually distinctive, with no effect on how the medicine works.
  • UNII XM0M87F357
    A dark iron oxide compound that gives medicines their black or dark color. It's used as a colorant in tablets and capsules to help identify the product and make it visually distinctive.
  • UNII 2G86QN327L
    Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
  • UNII 0VUT3PMY82
    Hypromellose 2910 is a plant-derived thickening agent made from cellulose. In medicines, it forms protective coatings on tablets or capsules, controls how fast the drug releases, and thickens liquid formulations.
  • UNII WZH3C48M4T
    Potassium hydroxide is a strong alkaline chemical used in medicines to adjust and maintain the pH level of liquid formulations, helping keep the product stable and the active ingredients effective.
  • UNII 46N107B71O
    Shellac is a natural resin secreted by the lac beetle. It's used as a coating on tablets and capsules to control how quickly the medicine dissolves and to improve appearance and stability.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
  • UNII C151H8M554
    A natural sugar derived from sugar cane or sugar beets. It's used as a sweetener, filler, and binder to improve taste, add bulk, and help hold tablet or capsule ingredients together.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

12 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAurobindo Pharma Limited
Labeler code59651
First marketedMar 2020
Product typeDrug For Further Processing
Portfolio1,456 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
8.2K
Units reimbursed last 4 qtrs
533K
Gross reimbursed last 4 qtrs
$146.5K
Avg / prescription
$17.86
Avg / unit
$0.2750
Latest quarter Q4 2025
2.2KRx
Medicaid pays / ea
$0.2750
gross reimbursed
vs
NADAC / ea
$0.0967
acquisition cost
=
Spread
+$0.1783
+184% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
53% FFS 47% MCO
Fee-for-service · 4,380 Rx Managed care · 3,827 Rx
State Medicaid map
Alaska: 1,160 units · 158 per 100k residents AK Maine: 15,312 units · 1,098 per 100k residents ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 10,524 units · 183 per 100k residents MN Wisconsin: no data reported WI Michigan: 10,988 units · 109 per 100k residents MI New York: 44,916 units · 230 per 100k residents NY Vermont: no data reported VT New Hampshire: 3,448 units · 246 per 100k residents NH Oregon: 4,498 units · 106 per 100k residents OR Nevada: 17,576 units · 550 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 24,169 units · 754 per 100k residents IA Illinois: 3,357 units · 26.8 per 100k residents IL Indiana: 8,466 units · 123 per 100k residents IN Ohio: 71,065 units · 603 per 100k residents OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: 222 units · 3.2 per 100k residents MA California: 168,239 units · 432 per 100k residents CA Utah: 5,280 units · 155 per 100k residents UT Colorado: 5,218 units · 88.8 per 100k residents CO Nebraska: 1,045 units · 52.8 per 100k residents NE Missouri: no data reported MO Kentucky: 2,871 units · 63.4 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: 4,430 units · 122 per 100k residents CT Rhode Island: no data reported RI Arizona: 3,419 units · 46.0 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 13,950 units · 196 per 100k residents TN North Carolina: 13,017 units · 120 per 100k residents NC South Carolina: no data reported SC Delaware: 974 units · 94.5 per 100k residents DE Oklahoma: 2,276 units · 56.2 per 100k residents OK Louisiana: 37,106 units · 811 per 100k residents LA Mississippi: no data reported MS Alabama: 18,970 units · 371 per 100k residents AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 36,956 units · 121 per 100k residents TX Florida: 3,518 units · 15.6 per 100k residents FL
Units reimbursed · per 100k residents
3.21,098
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Maine 1,098 /100k
2 Louisiana 811 /100k
3 Iowa 754 /100k
4 Ohio 603 /100k
5 Nevada 550 /100k
6 California 432 /100k
7 Alabama 371 /100k
8 New Hampshire 246 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
150 capsules this page59651-0315-77 8,207 Rx · $146,543
1500 capsules59651-0315-15 No Medicaid data
Drug total (last 4 qtrs): 8,207 Rx · 532,970 units · $146,543 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Aurobindo Pharma Limited supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Aurobindo Pharma Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 1500 capsules (59651-0315-15). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Aurobindo Pharma Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 59651-0314-77 · Aurobindo 59651-0316-77 · Aurobindo →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.